Review

Stem Cell Therapy to Treat Diabetes Mellitus

Chee Gee Liew¹, Peter W. Andrews²

Manuscript submitted November 10, 2008; resubmitted January 26, 2009; accepted February 9, 2009.

Keywords: type 1 diabetes, stem cell, beta-cell, transplantation, Pdx1, Sox9, NeuroD1, ngn3

Abstract

Transplantation of pancreatic islets offers a direct treatment for type 1 diabetes and in some cases, insulin-dependent type 2 diabetes. However, its widespread use is hampered by a shortage of donor organs. Many extant studies have focused on deriving β-cell progenitors from pancreas and pluripotent stem cells. Efforts to generate β-cells in vitro will help elucidate the mechanisms of β-cell formation and thus provide a versatile in vivo system to evaluate the therapeutic potential of these cells to treat diabetes. Various successful experiments using β-cells in animal models have generated extensive interest in using human embryonic stem cells to restore normoglycemia in diabetic patients. While new techniques are continually unveiled, the success of β-cell generation rests upon successful manipulation of culture conditions and the induction of key regulatory genes implicated in pancreas development. In this review, we compare successfully conducted protocols, highlight essential steps and identify some of the remarkable shortfalls common to these methods. In addition, we discuss recent advancements in the derivation of patient-specific pluripotent stem cells that may facilitate the use of autologous β-cells in stem cell therapy.

Fulltext: HTML , PDF (1.3 MB)

This article has been cited by other articles:

	Genetic analysis of type 1 diabetes: embryonic stem cells as new tools to unlock biological mechanisms in type 1 diabetes Holmes N, Cooke A Rev Diabet Stud 2012. 9(4):137-147
	Islet-derived stem cells from adult rats participate in the repair of islet damage Gong J, Zhang G, Tian F, Wang Y J Mol Histol 2012. Epub
	Pancreatic stem/progenitor cells for the treatment of diabetes Noguchi H Rev Diabet Stud 2010. 7(2):105-111
	Generation of insulin-producing cells from pluripotent stem cells: from the selection of cell sources to the optimization of protocols Liew CG Rev Diabet Sud 2010. 7(2):82-92
	Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG Am J Transplant 2010. 10(8):1870-1880